Moptim

Moptim stands as China’s pioneering force in ophthalmic OCT (Optical Coherence Tomography) technology, becoming the first domestic company to achieve OCT industrialization for ophthalmology. The company—whose name derives from “Medical Optical Imaging”—has grown from a university-industry collaboration into the market leader in China’s OCT segment, with products now serving eye care professionals across more than 40 countries.

Company Overview

Founded through a strategic partnership with Tsinghua University in 2005, Moptim established China’s first corporate laboratory dedicated to industrializing OCT technology for ophthalmology. This early commitment to research and development positioned the company as the domestic pioneer in a field long dominated by international players like Carl Zeiss.

The company operates under the umbrella of Shenzhen Certainn Technology Co., Ltd., which handles the entire manufacturing process from lens production and mechanical parts fabrication to final assembly. This vertical integration has enabled Moptim to achieve over 98% domestic component sourcing, a critical advantage for cost competitiveness and supply chain resilience.

In 2024, Moptim initiated IPO preparation with China Merchants Securities as the sponsor, signaling its transition toward becoming a publicly traded company. The company has been recognized as a National High-Tech Enterprise and holds ISO 13485 certification from TÜV SÜD.

Core Products

OCT/OCTA Systems

The Mocean series represents Moptim’s flagship diagnostic platform. The Mocean 4000, the company’s most advanced system, delivers 130,000 A-scans per second with AI-powered image enhancement and a 12×12mm 3D PanoScan capability. The system integrates real-time 45° SLO (Scanning Laser Ophthalmoscope) retinal imaging with eye tracking, enabling full assessment of retinal, glaucoma, and corneal conditions.

The Mocean 3000 series offers 50,000 A-scans per second with 5μm axial optical resolution, providing a cost-effective solution for clinical practices requiring high-quality OCT imaging.

Optical Biometry

The Colombo IOL series provides SD-OCT based biometry for cataract surgery planning. The Colombo IOL II uses 1050nm wavelength technology for superior cataract penetration, measuring up to 9 biometric parameters including axial length, keratometry, and choroidal thickness in a single scan.

Additional Diagnostic Equipment

Moptim’s portfolio extends to dry eye analysis (DEA system), non-contact tonometry (MT 160), slit lamp microscopy (SL-M6), and handheld auto-refractometry (easyRef series). The easyRef Pro and DEA dry eye analyzer have received FDA clearance for the US market.

Technology and Innovation

Moptim invests approximately 24% of revenue in research and development, exceeding the R&D intensity of many international competitors. The company holds 179 authorized patents including 11 PCT international patents, covering core technologies in OCT imaging, biometry, and diagnostic automation.

Key technological achievements include China’s first domestically developed posterior segment time-domain OCT and anterior segment time-domain OCT systems. The company’s AI algorithms for image enhancement and automated analysis represent its push toward intelligent diagnostics.

Market Presence

Moptim has established itself as the market leader in China’s OCT segment. According to Frost & Sullivan data, domestic OCT products captured over 50% market share in public hospital tenders by 2023, with Moptim among the leading domestic suppliers.

The company expanded internationally in 2018, establishing a European office in Athens, Greece. Products are now distributed through partners across Europe, the Americas, and Asia-Pacific markets. In the US market, Moptim works with OA Medical Eye to distribute FDA-cleared devices including the easyRef handheld refractometer and DEA dry eye analyzer.

Key Milestones

• 2005: Established China’s first OCT industrialization laboratory with Tsinghua University
• 2018: Opened European office in Athens; received first CE Mark for Mocean 3000 series
• 2021: Completed Series A funding from CAS-affiliated Guoke Ruihua Fund
• 2022: Secured Series A+ investment from Baidu Ventures
• 2024: Initiated IPO preparation with China Merchants Securities

Frequently Asked Questions

What products does Moptim manufacture?

Moptim produces ophthalmic diagnostic equipment across three categories: diagnostics (OCT/OCTA systems, optical biometers, tonometers, dry eye analyzers), refraction (handheld and table-mounted auto-refractometers, visual acuity testers), and surgical (operating microscopes). The company’s core strength lies in OCT technology.

Is Moptim publicly traded?

As of early 2024, Moptim has initiated IPO preparation with China Merchants Securities as the sponsor institution and Shenzhen Securities Regulatory Bureau as the oversight body. The company is not yet publicly traded.

Does Moptim have FDA-cleared products?

Yes. The easyRef handheld auto-refractometer and DEA dry eye analyzer have received FDA clearance and are available in the US market through distribution partner OA Medical Eye.